AI Terminal
Novonesis AS
Director's Dealing • Nov 20, 2024
3377_rpt_2024-11-20_2a13b18b-04c1-4581-8772-be4457b27bc1.pdf
Director's Dealing
Open in ViewerOpens in native device viewer
Trading by management and close relations of management
In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation) and commission delegated regulation (EU) 1052/2016 of 8 March 2016, Novozymes A/S, part of Novonesis Group reports the following transactions under ISIN DK0060336014, Novonesis (Novozymes) B shares under the symbol NSIS B.
| 1. | Details ofthe person discharging managerial responsibilities/person closely associated | |||
|---|---|---|---|---|
| a) | Name | Rainer Lehmann | ||
| 2. | Reason for the notification | |||
| a) | Position/status | CFO | ||
| b) | Initial notification/Amendment | Initial notification | ||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||
| a) | Name | Novozymes A/S, part of Novonesis Group | ||
| b) | LEI | 529900T6WNZXD2R3JW38 | ||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||
| a) | Description ofthe financial instrument, type of instrument |
B-shares | ||
| Identification code | DK0060336014 | |||
| b) | Nature of the transaction | Purchase of shares | ||
| c) | Price(s) and volume(s) | Volume 2,000 shares |
Price (DKK) 389.29055 |
|
| d) | Aggregated information - Aggregated volume - Price |
2,000 shares 778,581.10 DKK |
||
| e) | Date of the transaction | November 19, 2024 | ||
| f) | Place of the transaction | - Cboe Europe Equities - European Equities (Nl) - Nasdaq Copenhagen A/S - Turquoise Europe - Aquis Exchange Europe - Boerse Berlin |
November 20, 2024 Company announcement No. 47
Contact information
Tobias Bjorklund +45 3077 8682 [email protected]
Anders Enevoldsen +45 5350 1453 [email protected]
Katrine Spedtsberg Poulsen [email protected]
About Novonesis
Novonesis is a global leading biosolutions company transforming the way we all produce, consume and live. In more than 30 industries our biosolutions are helping companies meet their business needs and the needs of our planet. Our 10,000 people worldwide work closely with our partners and customers to challenge conventional thinking and transform business with biology.
CVR number: 10 00 71 27 – LEI: 529900T6WNZXD2R3JW38
Novozymes A/S, part of Novonesis Group Krogshoejvej 36 2880 Bagsvaerd Denmark
